• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Most patients stop using Wegovy, Ozempic for weight loss within two years

cafead

Administrator
Staff member
  • cafead   Jul 10, 2024 at 11:12: AM
via Only one in four U.S. patients prescribed Novo Nordisk’s (NOVOb.CO) Wegovy or Ozempic for weight loss were still taking the popular medications two years later, according to an analysis of U.S. pharmacy claims provided to Reuters that also showed a steady decline in use over time.

article source
 

<